Canaccord Genuity Reiterates a 'Buy' on Immunogen (IMGN); Raising PT
Tweet
Share
E-mailGet Alerts IMGN Hot Sheet
Price: $31.25 --0%
Rating Summary:
5 Buy, 17 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
5 Buy, 17 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Immunogen Inc. (NASDAQ: IMGN) price target raised from $14 to $17.
Canaccord analyst, George Farmer, said, "Ahead of T-DM1 developments expected from Roche on Nov. 7 and big catalysts expected next year, we increase our IMGN target to $17 from $14. We reiterate our BUY rating expecting continued stock momentum into next year."
For more ratings news on Immunogen Inc. click here and for the rating history of Immunogen Inc. click here.
Shares of Immunogen Inc. closed at $13.47 yesterday.
Canaccord analyst, George Farmer, said, "Ahead of T-DM1 developments expected from Roche on Nov. 7 and big catalysts expected next year, we increase our IMGN target to $17 from $14. We reiterate our BUY rating expecting continued stock momentum into next year."
For more ratings news on Immunogen Inc. click here and for the rating history of Immunogen Inc. click here.
Shares of Immunogen Inc. closed at $13.47 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Downgrades Alfen (ALFEN:NA) (ALFNF) to Hold
- Rubrik Inc (RBRK) PT Raised to $120 at Oppenheimer; Sees Another 'Beat and Raise'
- Jefferies Downgrades Sunway Healthcare Holdings (SUNMED:MK) to Hold
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
